Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
12.04
+0.03 (0.25%)
At close: Feb 20, 2026, 4:00 PM EST
12.19
+0.15 (1.25%)
After-hours: Feb 20, 2026, 7:48 PM EST
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
853.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 29.87M | -34.96M | -53.93% |
| Dec 31, 2017 | 64.83M | 23.21M | 55.77% |
| Dec 31, 2016 | 41.62M | 28.11M | 208.07% |
| Dec 31, 2015 | 13.51M | 12.97M | 2,406.31% |
| Dec 31, 2014 | 539.00K | -1.06M | -66.31% |
| Dec 31, 2013 | 1.60M | -4.42M | -73.43% |
| Dec 31, 2012 | 6.02M | 1.50M | 33.11% |
| Dec 31, 2011 | 4.52M | 2.42M | 114.92% |
| Dec 31, 2010 | 2.11M | 661.00K | 45.78% |
| Dec 31, 2009 | 1.44M | 274.00K | 23.42% |
| Dec 31, 2008 | 1.17M | -753.00K | -39.16% |
| Dec 31, 2007 | 1.92M | 1.52M | 380.75% |
| Dec 31, 2006 | 400.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xencor | 150.13M |
| Phathom Pharmaceuticals | 147.19M |
| ARS Pharmaceuticals | 142.77M |
| AbCellera Biologics | 35.33M |
| Arbutus Biopharma | 14.61M |
| Evommune | 13.00M |
| KalVista Pharmaceuticals | 1.43M |
OMER News
- 4 days ago - Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - Business Wire
- 25 days ago - Omeros Announces First Commercial Sales of YARTEMLEA® - Business Wire
- 6 weeks ago - Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript - Seeking Alpha
- 6 weeks ago - Omeros prices transplant complication drug at $36,000 per dose - Reuters
- 2 months ago - Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Business Wire
- 2 months ago - Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely - Seeking Alpha
- 2 months ago - Gold Edges Lower; Omeros Shares Jump - Benzinga
- 2 months ago - US FDA approves Omeros' drug to treat dangerous transplant complication - Reuters